265 terminated. 265 Phase 2, 54 Phase 3, 26 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 265 | Terminated 265 |
| Phase 3 | 54 | Terminated 54 |
| Phase 1 | 26 | Terminated 26 |
Follow Pneumonia: new trials by email Literature Review of Pneumonia trials Research Report on Pneumonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection SNG001, Placebo - Viral Pneumonia | Phase 2 | Terminated | Synairgen Research Ltd. | 11 | 2025-09-02 | 2026-09-14 |
| Evaluating Emetine for Viral Outbreaks (EVOLVE) Emetine Hydrochloride, Placebo - COVID-19 | Phase 2 / Phase 3 | Terminated | Johns Hopkins University | 4 | 2024-05-15 | 2026-01-23 |
| CX-4945 in Viral Community Acquired Pneumonia CX-4945 (SARS-CoV-2 domain), Placebo (SARS-CoV-2 domain), CX-4945 (Influenza virus domain) - Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia | Phase 2 | Terminated | Senhwa Biosciences, Inc. | 45 | 2024-03-20 | 2026-01-08 |
| Study of Obeldesivir in Children and Adolescents With COVID-19 Obeldesivir - COVID-19 | Phase 2 / Phase 3 | Terminated | Gilead Sciences | 3 | 2023-12-26 | 2025-02-03 |
| Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation Pregabalin, Independent walking training, Placebo - Chronic Fatigue Syndrome, COVID-19, Long Haul | Phase 2 | Terminated | National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland | 23 | 2023-10-24 | 2026-06-17 |
| Methylprednisolone in Patients With Cognitive Deficits in Post-COVID-19 Syndrome (PCS) Methylprednisolone - Post-COVID-19 Syndrome | Phase 2 | Terminated | Charite University, Berlin, Germany | 96 | 2023-10-01 | 2026-05-05 |
| Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly Comirnaty - Vaccination; Infection, COVID-19 | Phase 2 | Terminated | Radboud University Medical Center | 48 | 2023-09-26 | 2024-03-28 |
| Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA) Plitidepsin - COVID-19 | Phase 2 | Terminated | PharmaMar | 37 | 2023-04-19 | 2024-12-02 |
| Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals RVM-V001 30 µg, RVM-V002 30 µg, RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration - Infectious Disease, COVID-19 | Phase 1 / Phase 2 | Terminated | RVAC Medicines (US), Inc. | 24 | 2023-03-22 | 2023-10-16 |
| Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive. NP-101, Placebo - COVID-19 | Phase 2 | Terminated | Novatek Pharmaceuticals | 170 | 2023-02-22 | 2026-08-13 |
| Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19 AD17002 + Formulation buffer, Placebo - COVID-19 | Phase 2 / Phase 3 | Terminated | Advagene Biopharma Co. Ltd. | 180 | 2022-12-01 | 2025-09-10 |
| International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response Fostamatinib, Placebo - COVID-19, SARS-CoV2 Infection | Phase 2 / Phase 3 | Terminated | NEAT ID Foundation | 28 | 2022-10-27 | 2025-05-02 |
| Adrecizumab (HAM8101) to Improve Prognosis and Outcomes in COVID-19 Trial Adrecizumab (HAM 8101), Placebo - COVID-19 | Phase 2 | Terminated | Universitätsklinikum Hamburg-Eppendorf | 16 | 2022-10-06 | 2024-01-03 |
| Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants mRNA-1273.214, Placebo - SARS-CoV-2 | Phase 2 | Terminated | ModernaTX, Inc. | 68 | 2022-09-30 | 2025-11-26 |
| PBI-0451 (Pomotrelvir) Phase 2 Study in Nonhospitalized Symptomatic Adults With COVID-19 PBI-0451 (Pomotrelvir), Placebo - COVID-19 | Phase 2 | Terminated | Pardes Biosciences, Inc. | 242 | 2022-09-21 | 2024-12-11 |
| The KIN-FAST Trial (KIN001 For Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With SARS-CoV-2 KIN001, KIN001-Placebo - COVID-19 | Phase 2 | Terminated | Kinarus AG | 17 | 2022-08-25 | 2025-03-14 |
| Safety and Immunogenicity of COVID-19 Vaccine, AdCLD-CoV19-1 AdCLD-CoV19-1 - COVID-19, Vaccines | Phase 2 | Terminated | Cellid Co., Ltd. | 4 | 2022-08-19 | 2023-06-22 |
| A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19 AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061]) - Coronavirus Disease 2019 (COVID-19) | Phase 2 | Terminated | AstraZeneca | 251 | 2022-06-09 | 2024-10-23 |
| Evaluate the Efficacy and Safety of TF0023 in Treatments for COVID-19 in Hospitalized Adults TF0023 - COVID-19 Pneumonia | Phase 2 | Terminated | Techfields Inc | 19 | 2022-05-10 | 2024-01-08 |
| THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines AAHI-SC2 Vaccine, AAHI-SC3 Vaccine, EUA or approved vaccine - COVID-19 | Phase 1 / Phase 2 | Terminated | ImmunityBio, Inc. | 60 | 2022-05-05 | 2025-03-11 |
Showing 20 of 265. Sign in to see all of them.
COVID-19 (242) · Coronavirus Infections (52) · Respiratory Distress Syndrome (17) · Cytokine Release Syndrome (13) · Severe Acute Respiratory Syndrome (13) · Pneumonia, Viral (9) · Pneumonia, Ventilator-Associated (8) · Respiratory Tract Infections (8) · Lymphopenia (6) · Virus Diseases (6) · Respiratory Insufficiency (4) · Acute Lung Injury (3) · Community-Acquired Pneumonia (3) · Healthcare-Associated Pneumonia (3)
Respiratory Tract Diseases (263) · Infections (262) · Lung Diseases (262) · Respiratory Tract Infections (257) · RNA Virus Infections (245) · Coronaviridae Infections (244) · Nidovirales Infections (244) · Virus Diseases (241) · Pneumonia, Viral (237) · Coronavirus Infections (193) · Pathological Conditions, Signs and Symptoms (40) · Pathologic Processes (35) · Respiration Disorders (21) · Disease Attributes (17)
Standard of Care (20) · Hydroxychloroquine (17) · Sodium Chloride (15) · Azithromycin (9) · Saline Solution (9) · tocilizumab (7) · Interleukin-7 (5) · camostat (5) · Ascorbic Acid (4) · BNT162 Vaccine (4) · Colchicine (4) · Ivermectin (4) · Losartan (3) · Niclosamide (3) · Nitric Oxide (3)
Revimmune (5) · Charite University, Berlin, Germany (3) · Columbia University (3) · Johns Hopkins University (3) · Massachusetts General Hospital (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Pfizer (3) · Ampio Pharmaceuticals. Inc. (2) · Boehringer Ingelheim (2) · Corewell Health East (2) · Hackensack Meridian Health (2) · ImmunityBio, Inc. (2) · Innovent Biologics (Suzhou) Co. Ltd. (2) · Invivyd, Inc. (2) · McGill University Health Centre/Research Institute of the McGill University Health Centre (2)
United States (150) · Brazil (26) · Spain (24) · Germany (19) · France (16) · South Africa (16) · Canada (14) · Italy (14) · Mexico (13) · United Kingdom (13) · Belgium (12) · Poland (11) · Argentina (9) · Colombia (9) · Hungary (9)
Matthew Sims, MD PhD (2) · Michele L Donato, MD (2) · Mike Royal, MD (2) · Adit Ginde, MD MPH, (1) · Ahmed Kaseb, MD (1) · Alberto Zangrillo, MD PhD (1) · Allison J McGeer, MD (1) · Amanda L Stapleton, MD (1) · Amit Bar-Or, MD, FRCP (1) · Anders Kjellberg, MD (1) · Andreas Josefsson, MdPhD (1) · Andrew Badley, MD (1)
PMID 34473343, PMID 32031570, PMID 39903535, PMID 32171076, PMID 35244208, PMID 29515037, PMID 34658014, PMID 23053510, PMID 32788708, PMID 15030519, PMID 15885816, PMID 17276373, PMID 18230259, PMID 18434652, PMID 18752857, PMID 18946659, PMID 19190233, PMID 20463812, PMID 20607114, PMID 21287306, PMID 21423999, PMID 21732834, PMID 22496216, PMID 23357775, PMID 23412700, PMID 24981955, PMID 25050644, PMID 25496482, PMID 25666761, PMID 25816117, PMID 26166259, PMID 26472037, PMID 26872154, PMID 27080532, PMID 28325826, PMID 28880869, PMID 28895072, PMID 29038277, PMID 29041861, PMID 29414327, PMID 30668322, PMID 31986264, PMID 32075786, PMID 32091533, PMID 32108857, PMID 32109013, PMID 32112977, PMID 32125458, PMID 32142651, PMID 32167524
2023 (2), 2014 (1), 2016 (1), 2019 (1), 2UG1CA189859-06 (1), P20GM139745 (1), P30CA013330 (1), P30CA138292 (1), R01AG072301 (1), U01AI068632 (1), U54MD007601 (1), UM1AI109565 (1)